To address these limitations, we plan to use multiple NSCLC cell lines and patient-derived models in future studies, as well as examine erlotinib’s specificity using EGFR mutations that are not inhibited by erlotinib. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.